Home › Atopic Dermatitis (Eczema) › Indiana
Atopic Dermatitis (Eczema) clinical trials in Indiana
9 studies for Atopic Dermatitis (Eczema) are looking for participants at sites in Indiana.
Cities in Indiana
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 106, Plainfield
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Sep 29, 2026 · NCT07453602Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Clarksville
- Enveda Investigative Site, New Albany
- Enveda Investigative Site, West Lafayette
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Sep 25, 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- DS Research of Southern Indiana,LLC, Clarksville
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Aug 28, 2026 · NCT07599813A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Indianapolis
- Enveda Investigative Site, Plainfield
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Dawes Fretzin /ID# 265097, Indianapolis
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Aug 6, 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Options Research Group /ID# 264564, West Lafayette
RecruitingPhase 3
Ages 18 to 63 · All sexes · Updated Jul 6, 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- Southern Indiana Clinical Trials, New Albany
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8142, Indianapolis
- Galderma Investigational Site 7083, West Lafayette
RecruitingObservational study
Ages 12 and older · All sexes · Updated Mar 13, 2026 · NCT06988605From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.